Other non-cutaneous reactions with macrolides include QT prolongation (delayed heart ventricular response) and liver injury
An accumulating body of studies is showing positive potential for using GLP-1s for substance use, said Christian Hendershot, director of clinical research at the USC Institute for Addiction Science, Los Angeles
The good news is that most sleep-related issues resolve as treatment continues, and many patients ultimately sleep better due to reduced sleep apnea and nighttime reflux as weight decreases
This heightened amygdala activity corresponds to the rapid and craving-inducing reaction to the odor, aligning with the concept of food-related addictive behaviors
This potentially allows patients to achieve higher weight loss results, such as the 20.9% weight reduction seen in the 2022 SURMOUNT-1 clinical trial, without a proportional increase in gastrointestinal distress
Clinical Benefits of GIP Medications While research on GIP medications is still emerging, early results are promising